Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2007 Jan 23;96(3):514–518. doi: 10.1038/sj.bjc.6603575

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2007 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The impact of five possible vaccination strategies on the proportion of HPV16- associated cervical cancer cases prevented. Age 15 Female is a programme aimed at vaccinating 15-year-old female subjects annually, Age 15 Female+3 years Female is a programme vaccinating 15–18-year-old female subjects in the first year and 15-year-old female subjects in subsequent years, Age 12 Female+6 years Female is a programme vaccinating 12–18-year-old female subjects in the first year and 12- year-old female subjects in subsequent years, Age 15 Female and Male+3 years Female is a programme vaccinating 15–18-year-old female subjects and 15-year-old male subjects in the first year and 15-year-old male and female subjects in subsequent years, Age 12 Female and Male is a programme vaccinating 12-year-old female and male subjects annually and Age 12 Female and Male+3 years Female is a programme vaccinating 12–15-year-old female and 12 male subjects in the first year and 12-year-old male and female subjects in subsequent years.